Industries

Life Sciences and Clinical Translation

In life sciences the translation is part of the regulatory submission, not an accessory to it. Informed consent has to be understood by the participant, device instructions have to exist in the market's language to be sold there, and outcome measures have to be validated rather than merely translated.

Why do patient-reported outcome measures need back-translation?

Because a PRO instrument's score has to mean the same thing in every language, which is a measurement problem rather than a linguistic one. The established route is the ISPOR Principles of Good Practice, a multi-step process built to catch conceptual drift that a single translator would not see.

This is deliberately slower and more expensive than standard translation, and it is not substitutable. If an instrument is going to support an endpoint, the validation trail is part of what makes the data usable.

  • Two independent forward translations, then reconciliation into one version
  • Back translation into the source language by a translator who has not seen the original
  • Back translation review to resolve every discrepancy against the source concept
  • Harmonisation across languages, then cognitive debriefing with real patients

What languages does a device need for the EU and Brazil?

For the EU, Regulation 2017/745 leaves the specific languages to each member state, and in practice nearly all of them require their own official language for labelling and instructions for use. For Brazil, ANVISA submissions and product information are in Portuguese.

This turns language into a market-access decision: the countries you intend to sell into determine your translation scope and your update burden, because every labelling change propagates across every language version.

The practical mitigation is a maintained terminology base and translation memory across the whole product family, so a change to one warning is applied consistently everywhere instead of being retranslated from scratch each time.

Do you interpret for investigator meetings and audits?

Yes. Investigator meetings and advisory boards usually run with simultaneous interpreting, on site or remote. Inspections and site audits are consecutive, because the record has to be exact and the inspector controls the pace.

Frequently asked questions

Can machine translation be used in a regulated submission?

Not for anything a patient reads or a regulator relies on. It can support internal triage of literature or adverse event intake, with human review, but consent forms, labelling and instructions for use are human-translated and reviewed.

How do you handle document updates across many languages?

Through translation memory, so only changed segments are retranslated while the rest stays identical to the approved version. That keeps the update cost proportional to the change and avoids re-approving text that did not move.

Do you provide certificates of translation accuracy?

Yes, issued per document and naming the translator and reviewer. Where a submission requires notarisation or a sworn translator, tell us the receiving authority and we route it accordingly.

Clinical or regulatory translation to scope?

Send the document set and target markets. We scope per language and step.

Request a quote